Aclaris Therapeutics, Inc. Adjustments to Additional Paid in Capital, Warrant Issued
Aclaris Therapeutics, Inc. (ACRS) reported Adjustments to Additional Paid in Capital, Warrant Issued of $44.84 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-02-26
- Aclaris Therapeutics, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2020-03-31 was $378.00K.
- Aclaris Therapeutics, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2024 was $44.84M.
- Aclaris Therapeutics, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2020 was $378.00K.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|
| 2024-12-31 | $44.84M 10-K · filed 2026-02-26 | |
| 2020-12-31 | $378.00K 10-K · filed 2021-02-25 | |
| 2020-03-31 | $378.00K 10-Q · filed 2021-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |